Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NRP104 vs Adderall XR in children with ADHD
NCT00557011Phase 2Completed
- Sponsor
- New River Pharmaceuticals
- Start
- Sep 2004
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of lisdexamfetamine in attention deficit hyperactivity disorder (ADHD) (3 arms), sponsored by New River Pharmaceuticals. Primary endpoint: Swanson, Kotkin, Agler, M-Flynn, and Pelham Deportment Scale at 1 week. Started Sep 2004; status: completed.
02
Drugs
lisdexamfetamine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00557011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00557011.